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S U M M A R Y
Infections due to carbapenemase-producing Klebsiella pneumoniae represent an emerging threat due to
the high mortality rate and lack of valid antimicrobial combinations, especially when the strain is
colistin-resistant. We report a case of bloodstream infection due to pandrug-resistant K. pneumoniae
treated successfully with an innovative regimen comprising a combination of colistin plus double
carbapenem, along with an in vitro analysis showing the synergistic and bactericidal effect.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
Contents lists available at ScienceDirect
International Journal of Infectious Diseases
jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Infections due to carbapenemase-producing K. pneumoniae (CP-
Kp) have been recognized as an emerging challenge worldwide as
they are associated with a high mortality rate, especially when the
strain is colistin-resistant.1 Preliminary data suggest a role for
unconventional antibiotic combinations against colistin-resistant
CP-Kp, including colistin-based combinations.2 However, the role
of colistin in the setting of colistin-resistant strains is still debated.
Among innovative approaches, the use of a double-carbapenem
regimen has been proposed as a valid therapeutic option in severe
infections due to CP-Kp.3
The present report describes a case of bloodstream infection
due to pandrug-resistant (PDR) K. pneumoniae treated successfully
with an innovative regimen comprising a combination of colistin
plus double carbapenem. In vitro analysis of this regimen showed
the synergistic and bactericidal effect.* Corresponding author. Tel.: +39 0649970313-0773653745;
fax: +39 0649972625.
E-mail address: claudio.mastroianni@uniroma1.it (C.M. Mastroianni).
http://dx.doi.org/10.1016/j.ijid.2015.01.011
1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).2. Case report
A 75-year-old woman with a history of recent hip joint
placement was admitted to the Orthopaedic Department of
Sapienza University of Rome because of a delayed prosthetic joint
infection. She underwent a hip replacement and antibiotic-loaded
cement was placed. Intraoperative tissue and sonication ﬂuid
cultures grew Staphylococcus hominis resistant to methicillin and
susceptible to rifampicin, ﬂuoroquinolones, glycopeptides, and
daptomycin. Therapy with rifampicin 600 mg/day and daptomycin
8 mg/kg/day was started and the patient was transferred to the
Infectious Diseases Department. On admission, the patient was
afebrile. Her erythrocyte sedimentation rate (ESR) was 87 mm/h
and C-reactive protein (CRP) 9.63 mg/dl. A urinary catheter and
central venous catheter (CVC) were placed. During therapy with
intravenous rifampicin and daptomycin, normalization of the ESR
and CRP was observed. However, after 15 days of hospitalization
she developed a fever (body temperature 38.5 8C), hypotension,
and tachycardia. The white blood cell count was 4.7  109/l, ESR
60 mm/h, and CRP 9.01 mg/dl. A chest X-ray was negative and the
CVC was removed. Urine (105 CFU/ml) and blood cultures (n = 3)
were positive for PDR K. pneumoniae; CVC cultures grew PDR K.
pneumoniae and Acinetobacter baumannii resistant to carbapenemsciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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ml. Thus, rifampicin was stopped and intravenous therapy with
ertapenem 1 g/day and meropenem 2 g every 8 h was started. The
following day, intravenous colistin was added (loading dose
6 000 000 IU, then 4 500 000 IU every 12 h). After 48 h of therapy,
the patient remained febrile and blood cultures grew PDR K.
pneumoniae. After 96 h she became afebrile. Laboratory analyses
showed a reduction of the ESR and CRP. Blood and urine cultures
did not grow any organism. After 7 days of therapy, colistin was
stopped because of visual hallucinations, whereas the double
carbapenem regimen was continued for an additional 14 days, in
the absence of adverse events. The patient was discharged in good
condition; she was afebrile with an ESR of 31 mm/h and CRP of
0.9 mg/dl. She was then transferred to the Orthopaedic Depart-
ment for a new hip prosthesis replacement.
The VITEK-2 system was used for bacterial identiﬁcation and
antimicrobial susceptibility testing of the K. pneumoniae. In
addition, minimal inhibitory concentrations (MICs) of ertapenem
(ERT), meropenem (MEM), and colistin (COL) were determined by
broth macrodilution method (BMD) in accordance with the Clinical
and Laboratory Standards Institute guidelines.4 For COL testing, a
polysorbate 80 (Sigma-Aldrich) ﬁnal concentration of 0.002% was
used in order to avoid adherence of the drug to the tube wells.
Carbapenemase production was conﬁrmed phenotypically by
double disk synergy testing.5 Furthermore, the activity of MEM,
ERT, and COL, alone and in combination, was investigated by time–
kill studies using an initial inoculum of approximately 5  105
CFU/ml at the following concentrations: 1  MIC ERT, 1  MIC
MEM, 1  MIC COL, 0.5  MIC ERT + 0.5  MIC MEM, 0.5  MIC
ERT + 0.5  MIC MEM + 0.5  MIC COL, 1  MIC ERT + 1  MIC
MEM, and 1  MIC ERT + 1  MIC MEM + 1  MIC COL.
MICs of ERT, MEM, and COL, against the PDR K. pneumoniae
were 128, 256, and 32 mg/ml, respectively. In addition, MICs of
gentamicin and tigecycline were 8 and 4 mg/ml, respectively.
Phenotypic analyses showed that the isolate was a K. pneumoniae
carbapenemase (KPC) producer.
Despite an initial reduction in log CFU/ml, signiﬁcant regrowth
at 24 h was observed for ERT or MEM alone, whereas COL alone did
not lead to a reduction in the bacterial count at any point in time
(Figure 1).
When the double carbapenem combination was tested at a
concentration of MEM 0.5  MIC + ERT 0.5  MIC, bactericidalFigure 1. Time–kill studies for ertapenem, meropenem, colistin, ertapenem plus mer
Klebsiella pneumoniae isolated from a patient with a bloodstream infection. The horizont
count. GC, growth control; MEM, meropenem; ETP, ertapenem; COL: colistin.activity was achieved at 4, 6, and 8 h; however, regrowth
was observed at 24 h. In contrast, the bactericidal activity
was maintained for up to 24 h at concentrations of MEM
1  MIC + ERT 1  MIC.
Of note, the combination of ERT plus MEM plus COL showed
synergistic and bactericidal activity at 8 h, with the absence of
bacterial growth, which was maintained for up to 24 h at both
concentrations of ERT 0.5  MIC + MEM 0.5  MIC + COL 0.5  MIC
and ERT 1  MIC + MEM 1  MIC + COL 1  MIC (Figure 1).
3. Discussion
Carbapenem-resistant Enterobacteriaceae, including K. pneumo-
niae and Escherichia coli, show high levels of resistance to
carbapenems and other antimicrobial classes, with increasing
reports of colistin resistance.1 Therefore, in the absence of available
antimicrobials, new therapeutic approaches against these emer-
gent organisms are needed. Recently, the double carbapenem
regimen has been proposed as a valid therapeutic option in severe
infections due to PDR K. pneumoniae.3 Nowadays, the conventional
reporting of K. pneumoniae as resistant to all antimicrobials
appears not to be sufﬁciently informative for the clinician; thus the
performance of synergy testing in cases of infection due to PDR
strains might be useful in selecting the best antimicrobial
combination.
The case presented shows how the combination of colistin
with ertapenem plus meropenem was effective and synergistic
against a PDR K. pneumoniae causing bloodstream infection,
even in the presence of high MIC values. The rationale for the
use of colistin together with the double carbapenem regimen
resides in the disruption caused to the outer bacterial cellular
membrane by colistin allowing the other drugs to reach
adequate intracellular concentrations. Moreover, given the high
afﬁnity for carbapenemases, ertapenem binds to the hydrolytic
enzymes, acting as a suicide inhibitor and allowing the other
carbapenem to exert bactericidal activity. The synergistic effect
of this combination has been observed even in the setting of
high carbapenem resistance.3
In the killing curves, carbapenems alone had initial bactericidal
activity, but this was followed by signiﬁcant regrowth at 24 h. As
the MICs of both carbapenems were high, we could hypothesize
that the initial but temporary activity of these drugs alone was dueopenem, and ertapenem plus meropenem plus colistin against pandrug-resistant
al line represents a reduction of 3 log10 CFU/ml compared with the initial bacterial
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contrast, the combination of colistin with ertapenem plus
meropenem showed rapid bactericidal activity, even at sub-
inhibitory concentrations. Therefore, given the potent in vitro
effect and the good clinical outcome of the patient even after
colistin discontinuation, we suggest that colistin might be useful as
an initial therapeutic add-on against PDR organisms, rapidly
decreasing the bacterial amount and limiting drug toxicity.
In fact, our patient was treated with colistin plus double
carbapenem for 7 days and colistin was then stopped because of
adverse effects.6 Nevertheless, the patient recovered and the blood
cultures remained persistently negative after stopping colistin,
thus emphasizing the potential role of starting with colistin plus
double carbapenem and then simplifying to a less toxic regimen,
such as ertapenem plus meropenem. Additional in vitro and in vivo
studies are needed in order to provide more data on this innovative
therapeutic approach.
In conclusion, this case highlights how an innovative regimen
based on a short-course of colistin plus double carbapenems
followed by double carbapenems might be considered as a valid
and effective therapeutic strategy against severe infections caused
by PDR K. pneumoniae.Funding: This study was funded in part by a grant from Sapienza
University of Rome (2013).
Conﬂict of interest: None to declare.
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